These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 25263564)

  • 1. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
    Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
    Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
    Di Mitri D; Toso A; Chen JJ; Sarti M; Pinton S; Jost TR; D'Antuono R; Montani E; Garcia-Escudero R; Guccini I; Da Silva-Alvarez S; Collado M; Eisenberger M; Zhang Z; Catapano C; Grassi F; Alimonti A
    Nature; 2014 Nov; 515(7525):134-7. PubMed ID: 25156255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
    Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
    Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
    Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
    Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
    Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
    Kalathur M; Toso A; Chen J; Revandkar A; Danzer-Baltzer C; Guccini I; Alajati A; Sarti M; Pinton S; Brambilla L; Di Mitri D; Carbone G; Garcia-Escudero R; Padova A; Magnoni L; Tarditi A; Maccari L; Malusa F; Kalathur RK; A Pinna L; Cozza G; Ruzzene M; Delaleu N; Catapano CV; Frew IJ; Alimonti A
    Nat Commun; 2015 Jun; 6():7227. PubMed ID: 26085373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
    Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
    Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.
    Muñoz DP; Yannone SM; Daemen A; Sun Y; Vakar-Lopez F; Kawahara M; Freund AM; Rodier F; Wu JD; Desprez PY; Raulet DH; Nelson PS; van 't Veer LJ; Campisi J; Coppé JP
    JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31184599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts.
    Kabir TD; Leigh RJ; Tasena H; Mellone M; Coletta RD; Parkinson EK; Prime SS; Thomas GJ; Paterson IC; Zhou D; McCall J; Speight PM; Lambert DW
    Aging (Albany NY); 2016 Aug; 8(8):1608-35. PubMed ID: 27385366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
    Sapega O; Mikyšková R; Bieblová J; Mrázková B; Hodný Z; Reiniš M
    Int J Oncol; 2018 Nov; 53(5):1997-2009. PubMed ID: 30226595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How to limit the progression of PTEN-deficient prostatic tumors?].
    Grelet É; Parisotto M; Metzger D
    Med Sci (Paris); 2018 Nov; 34(11):904-906. PubMed ID: 30526823
    [No Abstract]   [Full Text] [Related]  

  • 16. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.
    Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY
    Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16392-7. PubMed ID: 21930937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
    Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
    Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
    Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy and PTEN in DNA damage-induced senescence.
    Sharma A; Almasan A
    Adv Cancer Res; 2021; 150():249-284. PubMed ID: 33858598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.